Comparison of the Biograph Vision and Biograph mCT for quantitative 90Y PET/CT imaging for radioembolisation

New digital PET scanners with improved time of flight timing and extended axial field of view such as the Siemens Biograph Vision have come on the market and are expected to replace current generation photomultiplier tube (PMT)-based systems such as the Siemens Biograph mCT. These replacements warrant a direct comparison between the systems, so that a smooth transition in clinical practice and research is guaranteed, especially when quantitative values are used for dosimetry-based treatment guidance. The new generation digital PET scanners offer increased sensitivity. This could particularly benefit 90Y imaging, which tends to be very noisy owing to the small positron branching ratio and high random fraction of 90Y. This study aims to determine the ideal reconstruction settings for the digital Vision for quantitative 90Y imaging and to evaluate the image quality and quantification of the digital Vision in comparison with its predecessor, the PMT-based mCT, for 90Y imaging in radioembolisation procedures. The NEMA image quality phantom was scanned to determine the ideal reconstruction settings for the Vision. In addition, an anthropomorphic phantom was scanned with both the Vision and the mCT, mimicking a radioembolisation patient with lung, liver, tumour, and extrahepatic deposition inserts. Image quantification of the anthropomorphic phantom was assessed by the lung shunt fraction, the tumour to non-tumour ratio, the parenchymal dose, and the contrast to noise ratio of extrahepatic depositions. For the Vision, a reconstruction with 3 iterations, 5 subsets, and no post-reconstruction filter is recommended for quantitative 90Y imaging, based on the convergence of the recovery coefficient. Comparing both systems showed that the noise level of the Vision is significantly lower than that of the mCT (background variability of 14% for the Vision and 25% for the mCT at 2.5·103 MBq for the 37 mm sphere size). For quantitative 90Y measures, such as needed in radioembolisation, both systems perform similarly. We recommend to reconstruct 90Y images acquired on the Vision with 3 iterations, 5 subsets, and no post-reconstruction filter for quantitative imaging. The Vision provides a reduced noise level, but similar quantitative accuracy as compared with its predecessor the mCT.

[1]  Marnix G. E. H. Lam,et al.  The value of yttrium-90 PET/CT after hepatic radioembolization: a pictorial essay , 2019, Clinical and Translational Imaging.

[2]  Alexander S. Pasciak,et al.  Radioembolization and the Dynamic Role of 90Y PET/CT , 2014, Front. Oncol..

[3]  Marnix G. E. H. Lam,et al.  Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization , 2013, PloS one.

[4]  Ronald Boellaard,et al.  Performance Characteristics of the Digital Biograph Vision PET/CT System , 2019, The Journal of Nuclear Medicine.

[5]  Ronald Boellaard,et al.  Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT , 2020, The Journal of Nuclear Medicine.

[6]  Marnix G. E. H. Lam,et al.  Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study , 2017, European Radiology.

[7]  Martin A Lodge,et al.  Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. , 2016, Medical physics.

[8]  Abass Alavi,et al.  Insights into the Dose–Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases , 2016, The Journal of Nuclear Medicine.

[9]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[10]  Denis Mariano-Goulart,et al.  Retrospective voxel-based dosimetry for assessing the body surface area model ability to predict delivered dose and radioembolization outcome , 2018 .

[11]  Maurizio Conti,et al.  Characterization of 176Lu background in LSO-based PET scanners , 2017, Physics in medicine and biology.

[12]  Jeroen Mertens,et al.  99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Max A. Viergever,et al.  Radioembolization lung shunt estimation based on a 90Y pretreatment procedure: A phantom study , 2018, Medical physics.

[14]  Marnix G E H Lam,et al.  99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.

[15]  Ashfaq Mahmood,et al.  Adsorption of metallic radionuclides on plastic phantom walls. , 2008, Medical physics.

[16]  P. Goa,et al.  Quantitative comparison of PET performance—Siemens Biograph mCT and mMR , 2016, EJNMMI Physics.

[17]  Marcus Hacker,et al.  Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors , 2015, The Journal of Nuclear Medicine.

[18]  S. Cheenu Kappadath,et al.  Comparison of Step-and-Shoot and Continuous-Bed-Motion PET Modes of Acquisition for Limited-View Organ Scans , 2017, The Journal of Nuclear Medicine Technology.

[19]  Denis Mariano-Goulart,et al.  Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome , 2018, The Journal of Nuclear Medicine.

[20]  T. Hellevik,et al.  Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation , 2014, Front. Oncol..

[21]  Michael Tapner,et al.  A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Gary D Hutchins,et al.  Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma. , 2014, Journal of vascular and interventional radiology : JVIR.

[23]  S. Gulec,et al.  Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Carlo Morosi,et al.  Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study , 2013, Hepatology.

[25]  J C Hung,et al.  Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. , 2000, Journal of the American Pharmaceutical Association.

[26]  Marnix G E H Lam,et al.  Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres , 2015, The Journal of Nuclear Medicine.

[27]  Max A. Viergever,et al.  Feasibility of imaging 90Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning , 2019, Medical physics.

[28]  Johan Nuyts,et al.  Bias Reduction for Low-Statistics PET: Maximum Likelihood Reconstruction With a Modified Poisson Distribution , 2015, IEEE Transactions on Medical Imaging.

[29]  Yuni K. Dewaraja,et al.  Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics , 2019, The Journal of Nuclear Medicine.

[30]  Casper Beijst,et al.  The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases , 2019, European Journal of Nuclear Medicine and Molecular Imaging.